Survodutide Phase III Trial for Obesity and NASH Completes Enrollment
Background
Obesity is a global health crisis often linked to serious metabolic complications, including Non-alcoholic Steatohepatitis (NASH), a progressive liver disease that can lead to cirrhosis and liver failure. Current treatments for NASH are limited, highlighting an urgent need for effective therapeutic strategies that address both weight management and liver health. This Phase III trial aimed to evaluate the efficacy and safety of Survodutide in reducing liver fat and promoting weight loss in individuals with obesity or overweight and confirmed or presumed NASH.
Study Design
Results
As of the provided record, the SYNCHRONIZE-MASLD trial has completed its enrollment of 218 participants, but the study's primary completion date is set for December 2, 2025. Therefore, specific efficacy and safety results for Survodutide compared to placebo are not yet publicly available. > The most important finding at this stage is that the trial successfully met its recruitment target, enrolling 218 individuals with obesity or overweight and NASH, indicating strong progress towards generating crucial data. Once available, the results are expected to detail Survodutide's impact on liver fat reduction and body weight changes over the 48-week treatment period, providing quantitative comparisons between the treatment and placebo arms.
Why It Matters
The successful completion of enrollment for this Phase III trial is a significant milestone in the development of new therapies for NASH and obesity. Given the limited treatment options for NASH, a condition affecting millions globally, a compound like Survodutide that targets both liver health and weight management could represent a major therapeutic advancement. Positive results from this study could pave the way for regulatory approval and clinical use of Survodutide as a novel treatment for individuals with NASH and concomitant obesity. The next critical step will be the analysis and publication of the 48-week efficacy and safety data, which will inform future clinical practice and potential market availability.